南美超级胎牛血清999尝鲜特惠转染试剂低至5折基质胶阶梯特惠积分商城,好礼送不停南美超级胎牛血清999尝鲜特惠转染试剂低至5折基质胶阶梯特惠积分商城,好礼送不停

翌圣生物 Yeasen|生命科学试剂与诊断原料一站式平台

TRIM72 alleviates skeletal muscle atrophy by modulating mt-dsRNA/RIG-I signaling

Liwei Liao, Ziwen Zheng, Weidong Xu, Junwei Guo, Simin Yao, Xinyue Huang, Zilin Wang, Chang Li, Jiaye Li, Qin Zhang, Yiding Bian, Kai Wang, Jinrui Miao, Ruixia Li, Han Wang, Xiaoming Zhou, Mingming D

Journal:METABOLISM-CLINICAL AND EXPERIMENTAL

IF:16.7

DOI:10.1016/j.metabol.2026.156696

PMID:42468159

Published:2026-07-17

research field:植物生物学遗传学信号转导分子植物-微生物互作逆境生理学病毒学

Abstract

Skeletal muscle atrophy is characterized by diminished muscle mass and function, which can arise from aging, nerve damage, and disease-related secondary atrophy. A central unresolved question is how these diverse stressors trigger common downstream mechanisms to cause sustained muscle deterioration. Here, we confirmed the role of cytosolic double-stranded RNA (dsRNA) in muscle atrophy across multiple murine models (aging, denervation and dexamethasone). Accumulated dsRNA released from damaged mitochondria aberrantly activated the innate immune sensor RIG-I signaling, triggering inflammation and muscle wasting. Moreover, adoptive transfer of mitochondrial dsRNA (mt-dsRNA) into healthy myotubes was sufficient to recapitulate the atrophic phenotype and activate RIG-I signaling. Furthermore, E3 ligase TRIM72 was identified as muscle-specific regulator of RIG-I signaling. TRIM72 attenuates the mt-dsRNA/RIG-I axis through two mechanisms. One is ubiquitinating RIG-I via interaction with its CARD domain to trigger degradation, the other is preserving mitochondria to prevent dsRNA leakage. Consequently, TRIM72 deficiency exacerbated atrophy while supplementation with recombinant TRIM72 (rhT72) improved muscle conditions and suppressed RIG-I signaling in vivo. In a clinic cohort, plasma TRIM72 level declined with muscle atrophy across multiple pathologies and rose with muscle recovery. Overall, our findings revealed mt-dsRNA/RIG-I axis as a key pathogenic pathway in muscle atrophy and identified TRIM72 as a key regulator and potential therapeutic agent.

本文使用的Yeasen产品

购物车
客服
转染试用